T0	Interventions 0 8	Afatinib
T1	Interventions 16 28	methotrexate
T2	Interventions 448 456	Afatinib
T3	Interventions 596 604	afatinib
T4	Interventions 619 631	methotrexate
T5	Interventions 1316 1397	EGFR-targeted antibody therapy (but not EGFR-targeted tyrosine-kinase inhibitors)
T6	Interventions 1476 1551	oral afatinib (40 mg/day) or intravenous methotrexate (40 mg/m(2) per week)
T7	Interventions 2344 2352	afatinib
T8	Interventions 2364 2377	methotrexate.
T9	Interventions 2472 2484	the afatinib
T10	Interventions 2499 2515	the methotrexate
T11	Interventions 3033 3044	in 44 (14%)
T12	Interventions 3074 3089	and 18 (11%) of
T13	Interventions 3121 3135	INTERPRETATION